AD:

#4/3. 9-19-02

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as first class mail in an envelope addressed to Box Sequence, P.O. Box 2327, the Commissioner for Patents, Arlington, Virginia 22202 on the date shown below.

Pane	April 2
1015	7
0 3003	<b>9</b>
MPR 3 0 2002	
TRAUE TRAUE	<b>S</b> /
TRADE	

April 25, 2002

Caral A

Docket No. GC700

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application:

Dunn-Coleman et al.

Group Art Unit: 1645

Serial No.: 10/028,245

Examiner: Unassigned

Filed: DECEMBER 18, 2001

For: EGVIII ENDOGLUCANASE AND NUCLEIC ACIDS

**ENCODING THE SAME** 

## **Preliminary Amendment**

Commissioner for Patents U.S. Patent and Trademark Office Box Sequence P.O. Box 2327 Arlington, VA 22202

Sir:

BI

Prior to examination, applicants respectfully request entry of the following amendments.

## In the specification:

In the specification after page 42 insert pages 1-3 enclosed herewith...

## On page 7, please replace the paragraph starting on line 5 with the following:

Figure 2 shows the predicted amino acid sequence (SEQ ID NO:2) and signal sequence (SEQ ID NO:3) based on the nucleotide sequence provided in Figure 1 (SEQ ID NO:1), wherein the signal sequence is indicated as bolded.

On page 19, please replace the paragraph starting on line 3 with the following:

Basic BLASTN search (www.ncbi.nlm.nih.gov/BLAST) of the non-redundant nucleic acid sequence database was conducted on September 12, 2001, with the *egl8* gene sequence presented in Figure 1 (SEQ ID NO:1), indicated that the only sequences producing significant

GC700 segpa